Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

When Sanofi cuts the price as of Jan. 1, Lantus will cost about $64 per vial. The company also announced a price cap that ensures no patient will pay more than $35 for a monthly supply of Lantus.

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.

Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.

Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%. By Ed Silverman March 16, 2023. Reprints. Ruby Wallau for STAT.

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January.

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...